Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the company. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Finally, Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS opened at $0.54 on Wednesday. The stock has a market capitalization of $30.04 million, a P/E ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $10.50. The firm’s 50 day moving average is $0.39 and its 200-day moving average is $0.96.

Institutional Trading of Marinus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in MRNS. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $28,000. AQR Capital Management LLC increased its position in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Marinus Pharmaceuticals during the second quarter worth about $64,000. World Investment Advisors LLC bought a new stake in Marinus Pharmaceuticals during the third quarter worth about $104,000. Finally, Deltec Asset Management LLC acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth approximately $107,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.